The breakthrough therapy program was established in 2012 to expedite the development and review of new medicines. We evaluated the times to approval, efficacy, and safety of breakthroughdesignated versus non-breakthrough-designated cancer drugs approved by the US Food and Drug Administration (FDA).
INTRODUCTION
In July 2012, Congress established the breakthrough therapy program to expedite the development and review of new medicines (Appendix Table A1 , online only). To qualify, a new medicine must be intended to treat a serious or life-threatening disease and, on the basis of preliminary clinical evidence, have the potential to offer substantial improvement over existing treatment options. 1 Sponsors of breakthrough-designated products receive intensive guidance from US Food and Drug Administration (FDA) reviewers and senior managers to facilitate shorter drug development and are eligible for rolling review of the marketing application. 2 These benefits seem to have contributed to reduced development times. 3 For example, pembrolizumab received breakthrough therapy designation in 2013 and was first approved by the FDA for the treatment of patients with unresectable or metastatic melanoma in September 2014, approximately 3 years after the start of its first-in-human clinical trial.
Cancer therapies represent 54% of the new breakthroughdesignated drugs approved from the program's inception through December 2017 (25 of 46), compared with 26% of all new drugs approved by the FDA during this period (58 of 221). 5 Despite the increasing frequency of breakthrough designations and approvals in oncology, the full implications of the breakthrough therapy program are not well understood. At the same time, physicians and patients have high expectations of products approved as breakthroughs. In two randomized survey studies, 94% of physicians and 92% of patients preferred a hypothetical cancer drug described as being labeled by the FDA as a breakthrough over an equally effective alternative without that moniker. 6, 7 Given the inconsistent health gains delivered by new cancer drugs, [8] [9] [10] recent initiatives, including work by ASCO's Cancer Research Committee, have sought to more clearly define clinically meaningful outcomes 11, 12 and promote better understanding of the value of new medicines. [13] [14] [15] [16] To understand the characteristics of drugs approved through this new program, we evaluated the efficacy and safety of breakthrough and nonbreakthrough cancer drugs. In addition, we compared the times to approval of breakthrough-designated versus non-breakthroughdesignated cancer drugs to characterize the relationship between breakthrough designation and speed of drug development.
METHODS

Sample Identification
We identified new cancer drugs approved by the FDA between January 1, 2012, and December 31, 2017, using the FDA's Drugs@FDA database. We focused on the first indication approved by the FDA, which represents the initial market availability of the drug for patients and clinicians. We linked approved products on our list with breakthrough therapy designation using the public lists of breakthrough therapy approvals published by the FDA's Center for Drug Evaluation and Research. 5 
Data Extraction
We extracted the dates of the Investigational New Drug (IND) application (marking the initiation of human trials) and first FDA approval, indication, mechanism of action, cancer type, treatment line (treatment naïve or experienced) and stage (advanced/metastatic or not), orphan designation (which provides tax and market exclusivity incentives to manufacturers of rare disease drugs), and expedited program (priority review, accelerated approval, fast track, and/or breakthrough designation) for all drugs in our study cohort.
Using a prespecified protocol, we then extracted key information from the FDA's Summary, Medical, and Integrated Multi-Disciplinary Reviews relating to the primary efficacy outcomes for the main, or pivotal, clinical trials relied on by the FDA to support regulatory approval (for all drugs, the trials designated as pivotal were indicated clearly in the FDA's review documents): overall survival (OS), progression-free survival (PFS), response rates (RRs), or other end points. For solid tumors, RRs were assessed as complete and partial responses according to Response Evaluation Criteria in Solid Tumors (RECIST), as summarized in the FDA documents. For controlled trials assessing OS or PFS, we evaluated whether the observed treatment effect was clinically meaningful. ASCO working groups have defined meaningful clinical trial goals for four cancer types (pancreatic, lung, breast, and colon), with targets for OS improvements ranging from 2.5 to 6 months. 11 Consistent with the authors of previous studies, 17 we considered OS gains of $ 2.5 months and PFS gains of $ 3 months for all cancer types to be clinically meaningful, a generous definition given that the ASCO criteria for meaningfulness were higher in certain cases (eg, . 4 months for FOLFIRINOX [leucovorin, fluorouracil, irinotecan, and oxaliplatin]-eligible patients with pancreatic cancer). We also collected the numbers of treated patients in the pivotal trial with any serious adverse event (as defined by the FDA) and deaths not related to progression of disease. Finally, two investigators (J.C.L. and T.J.H.) independently assessed the novelty of the mechanisms of action, with a novel mechanism of action defined as a pharmacologic target or biologic pathway for which the FDA had not yet approved a therapeutic agent; disagreements were resolved by consensus.
Statistical Analysis
The time to approval was calculated as the difference between the dates of IND and first FDA approval. We used Fisher's exact test to compare the distributions of categorical variables (expedited program, novel mechanism of action, trial end point) and the nonparametric KruskalWallis test to compare the median times to approval, OS and PFS gains (ie, improvement in the experimental v control arms), and RRs (for drugs for solid tumors) between breakthrough-designated and non-breakthroughdesignated drugs. We fit multivariable Cox regression models, including all studied variables regardless of statistical significance, to examine factors associated with times to approval. To evaluate the association between breakthrough therapy designation and (1) hazard ratios (HRs), (2) RRs, (3) serious adverse events, and (4) deaths, we used random-effects metaregression, which accounts for between-and within-study heterogeneity. For proportions (2, 3, and 4), CIs were calculated using the Wilson method, and variances of pooled estimates were stabilized using the Freeman-Tukey double arcsine transformation.
In sensitivity analyses, we repeated our analysis excluding drugs approved in 2012 and 2013, which may have been transition years as the FDA implemented the breakthrough program. In a post hoc analysis, we compared times to approval for drugs that received both breakthrough therapy designation and accelerated approval and drugs that received accelerated approval but not breakthrough therapy designation. To account for multiple testing, we used a modified Bonferroni correction known as the Simes procedure 18 to test the null hypothesis of no differences between breakthrough-designated and non-breakthrough-designated drugs across all significance tests on efficacy, novelty, and safety.
Statistical analyses were performed using Stata version 12.0 (StataCorp). Two-tailed P values , .05 were considered statistically significant. Institutional review board approval was not required because all the data were publicly available.
RESULTS
Between 2012 and 2017, the FDA approved 58 new cancer drugs, 55 (95%) of which were expedited under at least one program (Table 1) . Overall, 25 drugs (43%) received breakthrough therapy designation, whereas 26 (45%), 28 (48%), and 46 (79%) received accelerated approval, fast track, and priority review, respectively. Orphan drug designation was granted to 42 drugs (72%). The majority targeted solid tumors (37 [64%]) and were indicated for previously treated or refractory disease (36 [62%] ). Twenty-two drugs (38%) had novel mechanisms of action. Excluding drugs approved in 2012 and 2013, 23 (59%) received breakthrough therapy designation.
Time to First Approval
Breakthrough-designated cancer drugs were first approved by the FDA a median of 5.2 years after IND, compared with 7.1 years for non-breakthrough-designated drugs (difference, 1.9 years [27%]; P = .01; Table 2 ). Breakthrough-designated drugs were more likely to use accelerated approval (68% v 27%; P = .003) than were non-breakthrough-designated drugs but were not significantly more likely to use any other expedited program. Times to approval were also shorter among drugs with breakthrough designation and accelerated approval compared with those with accelerated approval but not breakthrough designation (4.8 v 8.3 years; P = .009). In multivariable Cox regression models controlling for all expedited programs, orphan drug designation, and drug, disease, and tumor characteristics, the interaction between breakthrough therapy designation and accelerated approval was the only significant predictor of times to approval (HR, 3.0; 95% CI, 1.4 to 6.4; P = .005; Fig 1) .
Novelty, RRs, and Survival
Of the 58 drug approvals, eight (14%) were approved primarily on the basis of OS, 19 (33%) primarily on the basis of PFS, two (3%) on the basis of both OS and PFS, one (2%) on the basis of invasive disease-free survival, and 28 (48%) on the basis of RRs. Of the 25 breakthrough-designated drugs, 16 (64%) were approved on the basis of RRs, eight (32%) on the basis of PFS, and one (4%) on the basis of OS (Table 3) . Significantly fewer drugs with versus without breakthrough therapy designation (4% v 27%) or accelerated approval (0% v 31%), but not priority review (17% v 17%) or fast track (25% v 10%), were approved on the basis of OS as a primary or co-primary end point.
Breakthrough-designated drugs were associated with numerically greater PFS gains compared with non-breakthrough drugs, although the difference between groups was not statistically significant (8.6 v 4.0 months; P = .11). There was no difference in median RRs (38% v 43%; P = .73) for drugs for solid tumors. Meta-regression analysis found no evidence across drugs for an association between breakthrough therapy status and HR for PFS (0.43 [95% CI, 0.27 to 0.59] v 0.51 [95% CI, 0.40 to 0.63]; P = .28; Fig 2) or RR (37% [95% CI, 26% to 49%] v 39% [95% CI, 30% to 50%]; P = .74; Fig 3) . Similar results were obtained when including trials where RR was not a primary end point (33% v 35%; P = .78).
The PFS gains for five of the six breakthrough-designated drugs and nine of the 12 non-breakthrough-designated drugs met the benchmark for a clinically meaningful improvement (ie, $ 3 months). Breakthrough-designated drugs were not more likely to act via a novel mechanism of action (36% v 39%; P = 1.00).
In sensitivity analyses, similar results were obtained excluding drugs approved in 2012 (when the breakthrough therapy program was created) and 2013.
Safety
In the pivotal studies of the cancer drugs in our study cohort, serious adverse events were reported in 2,586 of 6,857 treated †Only combinations of expedited programs with more than two observations are presented.
jco.org patients receiving breakthrough-designated drugs (38%), compared with 4,347 of 11,933 patients (36%) receiving non-breakthroughdesignated drugs (P = .93 for test for heterogeneity between subgroups from random-effects meta-regression). The proportion of deaths was not significantly different between breakthroughdesignated and non-breakthrough-designated drugs (6% v 4%; P = .99 from random-effects meta-regression).
Combining all hypothesis tests conducted on efficacy, safety, and novelty, the Simes procedure could not reject the null hypothesis of no differences between breakthrough-designated and nonbreakthrough-designated drugs.
DISCUSSION
In this analysis of cancer drugs approved by the FDA since the breakthrough therapy program's creation in 2012, we found that breakthrough-designated cancer drugs were approved by the FDA †Median progression-free survival was not reached for the experimental group in the pivotal trials for three drugs at the time of Food and Drug Administration approval. ‡Includes two drugs approved on the basis of both overall survival and progression-free survival. §Evaluated for solid tumor response rate (n = 13), progression-free survival gain (n = 18), and hazard ratio (n = 21). ║From random-effects meta-regression. ¶On the basis of ASCO criteria of improvement in progression-free survival of $ 3 months.
nearly 2 years before (or 27% faster than) non-breakthroughdesignated drugs. Twenty-four of 25 breakthrough-designated cancer drugs (96%) were approved on the basis of RRs or PFS. We found no statistically significant differences between breakthrough-designated and non-breakthrough-designated drugs in HRs for PFS, absolute PFS gains, RRs, or the proportions of drugs with clinically meaningful improvements in PFS or that had a novel mechanism of action. Congress created the breakthrough therapy program in response to concerns that "major breakthroughs in drugs and other treatments for debilitating and terminal diseases… [were] not always getting to patients though the most efficient and safe pathways."
19 Legislators hoped that this new program would ensure that "lifesaving treatments will be more readily available for patients."
20 Although breakthrough therapy designation was indeed associated with shorter times to approval, the study findings raise questions about the concordance between the available evidence of the efficacy and safety of breakthrough-designated medicines and the expectations that patients and physicians may hold for therapies described by the FDA as breakthroughs. In a national survey of Board-certified internists and specialists, 64% of respondents believed an FDA-designated breakthrough drug would represent a major advance over currently approved treatments for its indication, and 77% presumed there was high-quality evidence that the drug was more effective than approved treatments. 6 Similarly, in a survey of 597 American adults, 86% of respondents believed that a hypothetical lung cancer drug described as a breakthrough was more effective than other drugs. 7 Rigorous evidence of clinical benefits sufficient to meet the expectations of patients and physicians, as demonstrated by these surveys, may not be available for several years. Although some breakthrough approvals may eventually demonstrate clinical benefit commensurate with their designations, it is also possible that confirmatory studies for some costly drugs, including those preferentially prescribed after their approval with breakthrough designation, will fail to fulfill the full extent of these drugs' early promise. The eventual lack of evidence for clinical benefit in confirmatory studies-despite suggestive results from phase I and phase II trials-has been documented extensively, 9, 12, [21] [22] [23] [24] [25] and approximately 70% of new cancer drugs fail in late-stage trials because of concerns about efficacy, safety, or both.
26,27 For example, atezolizumab was approved by the FDA in 2016 with breakthrough designation and accelerated approval for patients with advanced urothelial carcinoma on the basis of durable and improved objective RRs compared with historical controls in a phase II trial of the drug. 28 However, in a recent phase III study (IMvigor211) in patients with platinum-refractory advanced or metastatic urothelial carcinoma, atezolizumab did not significantly improve OS compared with chemotherapy (11.1 v 10.6 months; HR, 0.87 [95% CI, 0.63 to 1.21]). 29 Prices for cancer drugs typically do not decline after their market introduction, even after negative trial results are announced. 30 Indeed, in January 2018, atezolizumab's wholesale acquisition cost increased by 1.5% to $8,749 per 3-week treatment cycle. With rapidly increasing cancer drug launch prices, 31 access to high-quality information about the benefits and risks of new therapies is important so that patients can make truly informed treatment decisions.
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To strengthen the breakthrough therapy program, patients and clinicians, in collaboration with regulators and other stakeholders, should have the opportunity to redefine the minimum level of expected clinical benefit needed to qualify for the breakthrough designation, an effort that could follow the model set by ASCO's Cancer Research Committee in developing benchmarks of clinically meaningful outcomes.
11 A higher and more transparent bar for breakthrough designation could ensure that the designation serves as a more reliable signal to patients in a manner that fulfills both legislative intent and patient expectations. More stringent criteria for breakthrough designation by the FDA may result in fewer products receiving the designation and the associated intensive agency guidance. As of December 2017, the FDA has granted 305 breakthrough therapy designations. 33 Given the significant resource demands reported by the FDA 34 in managing the program compared with the standard approval process, an overly expansive use of the breakthrough designation could dramatically dilute its value to companies and patients. Limiting the number of breakthrough designations could ensure that the benefits of this novel program are devoted to developers of truly transformative therapies. Importantly, such a change would not preclude the development and approval of medicines with more modest benefits under the FDA's other three expedited programs or the more general adoption by companies of best practices that could safely expedite the development times of all drugs during the collection of high-quality data about them.
This study has some limitations. First, because the breakthrough program was created only in 2012, follow-up on the products in our analysis was limited. We studied the evidence available to patients and clinicians at the time of approval; however, risk-benefit profiles may change as confirmatory studies are completed and other evidence is collected. Second, although our study included all new FDA-approved drugs, it was not powered to detect marginal differences between breakthroughdesignated and non-breakthrough-designated products. Of course, the breakthrough therapy program was not originally intended for drugs with marginal differences, nor is it currently perceived to be applied to such drugs. Third, there are inherent challenges in assessing drugs on the basis of limited information, and greater attention to the lack of surrogate measures that are well correlated with survival or other patient-important outcomes is needed. We did not consider alternative measures of clinical benefit that have been proposed, such as restricted mean survival time 35 and milestone outcomes 36 ; these measures may be relevant in some cases (eg, in the interpretation of recent immunotherapy trials 37 ), but there is no consensus on their use. 
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The breakthrough therapy designation was established in 2012 to speed the development and approval of medicines representing transformative advances in clinical care. Early evidence with this program indicates that breakthrough-designated cancer medicines were associated with faster times to approval than were nonbreakthrough products. Although some therapies demonstrated clinically meaningful benefits, to date there is little evidence that breakthrough-designated cancer medicines offer substantially improved efficacy or safety or are more likely to act via a novel mechanism of action, as compared with non-breakthroughdesignated drugs. Continued follow-up, rigorous confirmatory studies, and more robust and transparent criteria for breakthrough designation are needed for patients and clinicians to distinguish true breakthroughs from those that are breakthroughs in name only.
